

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Imugene Limited
<b>ABN</b>	99 009 179 551

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Paul Hopper
<b>Date of last notice</b>	8 July 2024

#### **Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Director's related parties
<b>Date of change</b>	N/A
<b>No. of securities held prior to change</b>	(1) Direct Shares - 4,275,736 ORDINARY FULLY PAID SHARES (1,381,422 Shares - Subject to voluntary escrow 12m after issue date) (2) Indirect Shares - 404,796,170 ORDINARY FULLY PAID SHARES (110,790,024 Shares - Subject to voluntary escrow 12m after issue date) (3) 2,900,000 - ESOP OPTIONS (4) 2,916,666 - LISTED OPTIONS @ \$0.118, expiring 31 August 2026 (5) 2,926,125 - PERFORMANCE RIGHTS
<b>Class</b>	N/A
<b>Number acquired</b>	N/A

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	N/A
<b>No. of securities held after change</b>	(1) Direct Shares - 4,275,736 ORDINARY FULLY PAID SHARES (1,381,422 Shares - Subject to voluntary escrow 12m after issue date) (2) Indirect Shares - 404,796,170 ORDINARY FULLY PAID SHARES (110,790,024 Shares - Subject to voluntary escrow 12m after issue date) (3) 2,900,000 - ESOP OPTIONS (4) 2,916,666 - LISTED OPTIONS @ \$0.118, expiring 31 August 2026 (5) 2,926,125 - PERFORMANCE RIGHTS
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	(see change of director's relevant interests in contracts below)

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Pursuant to an ASX announcement dated 23 December 2020, Executive Chairman, Paul Hopper, advises that the Funding Arrangement referred to therein, has been varied by an additional 80.2 million shares for a term of thirty six months.
<b>Nature of interest</b>	The varied Funding Arrangement includes a loan facility referencing 80.2 million Imugene Limited shares.
<b>Name of registered holder (if issued securities)</b>	Moreglade Pty Ltd
<b>Date of change</b>	25 September 2024
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.

For personal use only